Muriel Picard
Overview
Explore the profile of Muriel Picard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Meert A, Toffart A, Picard M, Jaubert P, Gibelin A, Bauer P, et al.
Bull Cancer
. 2022 Jun;
109(9):916-924.
PMID: 35718570
Purpose: To study prevalence of targeted therapy (TT)-related adverse events requiring ICU admission in solid tumor patients. Methods: Retrospective multicenter study from the Nine-i research group. Adult patients who received...
12.
Bosc C, Saland E, Bousard A, Gadaud N, Sabatier M, Cognet G, et al.
Nat Cancer
. 2022 Feb;
2(11):1204-1223.
PMID: 35122057
Therapy resistance represents a major clinical challenge in acute myeloid leukemia (AML). Here we define a 'MitoScore' signature, which identifies high mitochondrial oxidative phosphorylation in vivo and in patients with...
13.
Picard M, Sterin A, Bay J, Courbon C, Moreau A, Paul F, et al.
Bull Cancer
. 2022 Jan;
110(2S):S123-S131.
PMID: 35094839
The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is...
14.
Largeaud L, Bertoli S, Berard E, Tavitian S, Picard M, Dufrechou S, et al.
Blood Cancer J
. 2022 Jan;
12(1):4.
PMID: 34987148
No abstract available.
15.
Tudesq J, Yakoub-Agha M, Bay J, Courbon C, Paul F, Picard M, et al.
Bull Cancer
. 2021 Dec;
110(2S):S116-S122.
PMID: 34895696
The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such...
16.
Paul F, Vicente C, Courbon C, Moreau A, Picard M, Pochon C, et al.
Bull Cancer
. 2021 Dec;
108(12S):S90-S97.
PMID: 34876272
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms...
17.
Valade S, Picard M, Mokart D, Calvet L, Bruneel F, de Montmollin E, et al.
Mycoses
. 2021 Dec;
65(2):226-232.
PMID: 34856032
Objectives: Geotrichum spp can be responsible for severe infections in immunocompromised patients. We aim to describe Geotrichum-related infections in the ICU and to assess risk factors of mortality. Methods: Retrospective...
18.
Agbakou M, Mekontso-Dessap A, Pere M, Voiriot G, Picard M, Bourenne J, et al.
Sci Rep
. 2021 Dec;
11(1):23132.
PMID: 34848756
Little is known about patients with sickle cell disease (SCD) who require intensive care unit (ICU) admission. The goals of this study were to assess outcomes in patients admitted to...
19.
Pochon C, Courbon C, Bay J, Moreau A, Paul F, Picard M, et al.
Bull Cancer
. 2021 Nov;
108(12S):S98-S103.
PMID: 34802718
CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell...
20.
Morel G, Mulier G, Ghrenassia E, Abdel Nabey M, Tandjaoui Y, Kouatchet A, et al.
Emerg Infect Dis
. 2021 Jun;
27(7):1840-1849.
PMID: 34153220
No abstract available.